Quest Diagnostics Inc vs Vistra Corp — how do they compare? Quest Diagnostics Inc trades at $236.56 (market cap $26.21B), while Vistra Corp trades at $146.98 (market cap $48.64B). The key difference: Vistra Corp is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | VST | |
|---|---|---|
Market Cap | $26.21B | $48.64B |
Sector | Health | Technology |
52-Week High | $238.50 | $217.92 |
52-Week Low | $173.49 | $134.71 |
Enterprise Value | $31.97B | $70.58B |
Dividend Yield | 1.45% | 0.63% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
VST trades at $147.54, up 3.27% today, with strong analyst support (90.9% buy ratings) and a $239.75 consensus price target suggesting 62% upside. Recent Q2 2026 earnings showed mixed results with an EPS miss but 30% EBITDA growth to $1.77 billion, driven by data center demand. Technical indicators are bearish with support at $141, while fundamentals show robust profitability (11.55% net margin) offset by high valuation multiples (P/E 24.44).
The outlook remains positive given Vistra's positioning in the AI-powered data center boom, though risks include ERCOT pricing volatility and hedging losses. With institutional ownership stable and dividend payments consistent, the stock offers growth exposure to electricity demand trends, but investors should monitor execution on 2026 guidance and competitive pressures in the utility sector.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →